Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - candesartanum cílexetíl; hydrochlorothiazide - tafla - 16 mg/12,5 mg

Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

n.v. organon* - betamethasonum dínatríumfosfat; betamethasonum díprópíónat - stungulyf, dreifa - 5+2 mg/ml

Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - dabigatran etexilate mesilate - venous thromboembolism; arthroplasty, replacement - blóðþurrðandi lyf - prevention of venous thromboembolic events.

Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

instituto grifols s.a. - mönnum eðlilegt að notkun - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - Ónæmiskerfið sera og mótefni, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - kyrningahvítblæði, eitilfrumnafæð, langvarandi, b-frumur - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

amdipharm limited* - acetazolamidum inn - tafla - 250 mg

Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - naproxenum inn - magasýruþolin tafla - 250 mg

Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - naproxenum inn - magasýruþolin tafla - 500 mg

Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - blóðþurrðandi lyf - notkun þess hjá, sam gefið með asetýlsalisýlsýru (asa), er ætlað til að fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklingar withacute kransæðastíflu heilkennum (haft) ora sögu um kransæðastíflu (mi) og mikil hætta á að þróa atherothrombotic eventbrilique, sam-gefið með asetýl salicýlsýru (asa), er ætlað til að fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga með sögu um kransæðastíflu (mi átti sér stað að minnsta kosti einu ári síðan) og mikil hætta á að þróa atherothrombotic ef.

Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

h. lundbeck a/s - vortioxetine - Þunglyndi, major - psychoanaleptics, - meðferð við alvarlegum þunglyndisþáttum hjá fullorðnum.